Levetiracetam Online



How and where to order Levetiracetam (Keppra) 250 mg, 500 mg, 750 mg, 1000 mg tablets or capsules online on the National Movement for America's Children website:

Shop:CHEAP MEDS FOR SALE
Stores:PHARMA DOCTOR
Prices:from $0.79 per pill
Discount:5% coupon: 5OFF
Forms:Keppra 250 mg, 500 mg, 750 mg, 1000 mg tablets
Quantity:10-270 pills
Type:Levetiracetam brand, Keppra generic
Payment:Visa, Mastercard, AmEx, E-Check (ACH), Bitcoin
Delivery:Regular and express mail service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


Levetiracetam (trade names include Keppra, Epilive, Keppra-XR, Levetiracetam Actavis, Levepsy, Levetiracetam Mylan, Levera, Levesam, Levetiracetam Sandoz, Levipil, Levetiracetam Teva, Levipil-XR, Torleva) is an anticonvulsant, antiepileptic drug. This medication is used in the therapy of epilepsy for epileptic patients as add-on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy, focal epilepsy, status epilepticus, myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy, partial-complex epilepsy, partial onset seizures in patients 4 years of age and older, seizures associated with autism spectrum disorder, for prevention of seizures. It is in research studies to treat some neurologic conditions, Tourette syndrome, anxiety disorder, to reduce hyperactivity in the hippocampus in Alzheimer's disease. Levetiracetam works by decreasing abnormal excitement in the brain. Keppra is non-addictive and generally well tolerated medication.


Keppra (Levetiracetam)


Related medications:

  • Beclamide (Neuracen)
  • Carbamazepine (Tegretol)
  • Carbidopa, Levodopa (Sinemet)
  • Carisbamate (Comfyde)
  • Divalproex (Depakote)
  • Felbamate (Felbamyl)
  • Gabapentin (Neurontin)
  • Lacosamide (Vimpat)
  • Lamotrigine (Lamictal)
  • Oxcarbazepine (Trileptal)
  • Perampanel (Fycompa)
  • Phenacemide (Phenurone)
  • Pheneturide (Benuride)
  • Phenytoin (Dilantin)
  • Piracetam (Nootropil)
  • Pregabalin (Lyrica)
  • Primidone (Mysoline)
  • Retigabine (Trobalt)
  • Stiripentol (Diacomit)
  • Sultiame (Ospolot)
  • Topiramate (Topamax)
  • Zonisamide (Zonegran)


    Pharmacological and medical categories:

  • Anticonvulsants
  • Antiepileptic drugs
  • Neurological medications


    ATC codes:

  • N - Nervous system
  • N03 - Antiepileptics
  • N03A - Antiepileptics
  • N03AX - Other antiepileptics
  • N03AX14 - Levetiracetam


    ICD-10 codes:

  • Pervasive developmental disorders - F84
  • Autistic disorder - F84.0
  • Epilepsy and recurrent seizures - G40
  • Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset - G40.0
  • Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures - G40.1
  • Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures - G40.2
  • Generalized idiopathic epilepsy and epileptic syndromes - G40.3
  • Epileptic seizures related to external causes - G40.5
  • Epilepsy, unspecified, not intractable, with status epilepticus - G40.901
  • Juvenile myoclonic epilepsy, intractable, with status epilepticus - G40.B11


    Indications and usage:

    Keppra (Levetiracetam) tablets and oral solution are indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
    This medication is prescribed for adjunctive therapy for the treatment of:

  • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy.
  • Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.


    Dosage and administration:

  • Use the oral solution for pediatric patients with body weight <= 20 kg.
  • For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon).

    Partial-onset seizures (monotherapy or adjunctive therapy)

  • 1 month to < 6 months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily.
  • 6 months to < 4 years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily.
  • 4 years to < 16 years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.
  • Adults 16 years and older: 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily.

    Myoclonic seizures in adults and pediatric patients 12 years and older

  • 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily.

    Primary generalized tonic-clonic seizures

  • 6 years to < 16 years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.
  • Adults 16 years and older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily.

    Adult patients with impaired renal function

  • Dose adjustment is recommended, based on the patient's estimated creatinine clearance.


    Dosage forms and strengt:

  • Keppra (Levetiracetam) 250 mg, 500 mg, 750 mg, and 1000 mg film-coated, scored tablets.
  • Keppra (Levetiracetam) 100 mg/ml oral solution.


    Overdosage:

    Signs, symptoms and laboratory findings of acute overdosage in humans

    The highest known dose of Keppra received in the clinical development program was 6000 mg/day. Other than drowsiness, there were no adverse reactions in the few known cases of overdose in clinical trials. Cases of somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses in postmarketing use.

    Management of overdose

    There is no specific antidote for overdose with Levetiracetam (Keppra). If indicated, elimination of unabsorbed drug should be attempted by emesis or gastric lavage; usual precautions should be observed to maintain airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the patient's clinical status. A Certified Poison Control Center should be contacted for up to date information on the management of overdose with Keppra.

    Hemodialysis

    Standard hemodialysis procedures result in significant clearance of levetiracetam (approximately 50% in 4 hours) and should be considered in cases of overdose. Although hemodialysis has not been performed in the few known cases of overdose, it may be indicated by the patient's clinical state or in patients with significant renal impairment.


    Contraindications:

    Known hypersensitivity to levetiracetam; angioedema and anaphylaxis have occurred.


    Warnings and precautions:

  • Behavioral abnormalities including psychotic symptoms, suicidal ideation, irritability, and aggressive behavior have been observed; monitor patients for psychiatric signs and symptoms.
  • Suicidal behavior and ideation: monitor patients for new or worsening depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior.
  • Monitor for somnolence and fatigue and advise patients not to drive or operate machinery until they have gained sufficient experience on Keppra.
  • Serious dermatological reactions: discontinue Keppra (Levetiracetam) tablets or solution at the first sign of rash unless clearly not drug related.
  • Coordination difficulties: monitor for ataxia, abnormal gait, and incoordination. Advise patients to not drive or operate machinery until they have gained experience on this medicine.
  • Withdrawal seizures: Keppra must be gradually withdrawn.


    Adverse reactions, side effects:

    Most common adverse reactions of levetiracetam (incidence >= 5% more than placebo) include:

  • Adult patients: somnolence, asthenia, infection, dizziness.
  • Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, irritability.

    To report suspected side effects of Keppra (Levetiracetam) tablets, injections, and oral solution contact UCB pharmaceutical company or your local FDA.


    Drug interactions:

    Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.


    Use in specific populations:

    Pregnancy

    Plasma levels of levetiracetam may be decreased and therefore need to be monitored closely during pregnancy. Based on animal data, may cause fetal harm.

    Lactation

    Levetiracetam is excreted in human milk. There are no data on the effects of Keppra on the breastfed infant, or the effects on milk production.

    The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Keppra and any potential adverse effects on the breastfed infant from this drug or from the underlying maternal condition.

    Pediatric use

    The safety and effectiveness of Levetiracetam (Keppra) for the treatment of partial-onset seizures in patients 1 month to 16 years of age have been established. The dosing recommendation in these pediatric patients varies according to age group and is weight-based.


    Patient counseling information:

    Psychiatric reactions and changes in behavior

    Advise patients that Keppra (Levetiracetam) may cause changes in behavior (e.g. aggression, agitation, anger, anxiety, apathy, depression, hostility, and irritability) and psychotic symptoms.

    Suicidal behavior and ideation

    Counsel patients, their caregivers, and/or families that antiepileptic drugs (AEDs), including Keppra, may increase the risk of suicidal thoughts and behavior and advise patients to be alert for the emergence or worsening of symptoms of depression; unusual changes in mood or behavior; or suicidal thoughts, behavior, or thoughts about self-harm. Advise patients, their caregivers, and/or families to immediately report behaviors of concern to a healthcare provider.

    Effects on driving or operating machinery

    Inform patients that levetiracetam may cause dizziness and somnolence. Inform patients not to drive or operate machinery until they have gained sufficient experience on Keppra to gauge whether it adversely affects their ability to drive or operate machinery.

    Anaphylaxis and angioedema

    Advise patients to discontinue Keppra and seek medical care if they develop signs and symptoms of anaphylaxis or angioedema.

    Dermatological adverse reactions

    Advise patients that serious dermatological adverse reactions have occurred in patients treated with Levetiracetam (Keppra) and instruct them to call their physician immediately if a rash develops.

    Withdrawal of Keppra

    Advise patients and caregivers not to discontinue use of this medication without consulting with their healthcare provider. Keppra (Levetiracetam) should normally be gradually withdrawn to reduce the potential of increased seizure frequency and status epilepticus.

    Pregnancy

    Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during Keppra therapy. Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry if they become pregnant.


    Pregnancy categories:

  • B3 - Australia
  • C - United States (Risk cannot be ruled out)


    Salts and other forms:

  • Levetiracetam Base
  • Levetiracetam Dihydrochloride


    Synonyms, international and chemical names:

  • Etiracetam Levo-Isomer
  • Levetiracetamum
  • Levetyracetam
  • Levitiracetam
  • Levotiracetam
  • Lewetyracetam


    Brands, generics, trade names:

  • CO Levetiracetam - Cobalt Pharmaceuticals
  • Epifast - Magnet Labs
  • Epilive - Lupin Pharmaceuticals
  • Ivetra - Torrent Pharmaceuticals
  • Keppra - UCB Pharma
  • Keppra-XR - UCB Pharma
  • Kopodex - Drugtech Laboratorio, Recalcine Laboratorios
  • Levefree - Pfizer
  • Levenue - Alkem Laboratories
  • Levepsy - Cipla
  • Levera - Intas Pharmaceuticals
  • Levera-XR - Intas Pharmaceuticals
  • Levesam - Abbott
  • Levetiracetam - Actavis, Apotex, Cipla, Mylan, Sandoz, Teva, Wockhardt
  • Levilex - Abbott
  • Levipil - Sun Pharmaceutical Industries
  • Levipil-XR - Sun Pharmaceutical Industries
  • Levitam - Aspen
  • Levroxa - Ranbaxy
  • Levtam - Unichem Laboratories
  • Torleva - Torrent Pharmaceuticals
  • Torleva-XR - Torrent Pharmaceuticals


    Here is a list of popular medications containing levetiracetam as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    Keppra
  • Injectable; Infusion; Levetiracetam 100 mg / ml
  • Solution; Oral; Levetiracetam 100 mg / ml
  • Tablets, Film-Coated; Oral; Levetiracetam 250 mg
  • Tablets, Film-Coated; Oral; Levetiracetam 500 mg
  • Tablets, Film-Coated; Oral; Levetiracetam 750 mg
  • Tablets, Film-Coated; Oral; Levetiracetam 1 g
  • UCB Pharma
  • Aesica Pharmaceuticals
  • Firma Chun Cheong
  • GlaxoSmithKline
  • Lundbeck
  • NextPharma
  • Olic Thailand
  • Rontag Laboratorios
  • United Drug
  • Zuellig Pharma
  • Keppra-XR
  • Tablets, Extended Release; Oral; Levetiracetam 500 mg
  • Tablets, Extended Release; Oral; Levetiracetam 750 mg
  • UCB Pharma
  • Levepsy
  • Tablets; Oral; Levetiracetam 250 mg
  • Tablets; Oral; Levetiracetam 500 mg
  • Cipla
  • Levesam
  • Injectable; Injection; Levetiracetam 100 mg / ml
  • Liquid; Oral; Levetiracetam 100 mg / ml
  • Tablets; Oral; Levetiracetam 250 mg
  • Tablets; Oral; Levetiracetam 500 mg
  • Tablets; Oral; Levetiracetam 750 mg
  • Abbott
  • Piramal Healthcare
  • Levetiracetam
  • Tablets; Oral; Levetiracetam 250 mg
  • Tablets; Oral; Levetiracetam 500 mg
  • Tablets; Oral; Levetiracetam 750 mg
  • Tablets; Oral; Levetiracetam 1 g
  • Sandoz
  • Levetiracetam
  • Tablets, Extended Release; Oral; Levetiracetam 500 mg
  • Tablets, Extended Release; Oral; Levetiracetam 750 mg
  • Tablets; Oral; Levetiracetam 250 mg
  • Tablets; Oral; Levetiracetam 500 mg
  • Tablets; Oral; Levetiracetam 750 mg
  • Tablets; Oral; Levetiracetam 1 g
  • Teva
  • Levipil
  • Injectable; Injection; Levetiracetam 100 mg / ml
  • Solution; Oral; Levetiracetam 100 mg / ml
  • Tablets; Oral; Levetiracetam 250 mg
  • Tablets; Oral; Levetiracetam 500 mg
  • Sun Pharmaceutical Industries
  • Torleva
  • Syrup; Oral; Levetiracetam 500 mg / 5 ml
  • Tablets, Film-Coated; Oral; Levetiracetam 250 mg
  • Tablets, Film-Coated; Oral; Levetiracetam 500 mg
  • Tablets, Film-Coated; Oral; Levetiracetam 750 mg
  • Tablets, Film-Coated; Oral; Levetiracetam 1 g
  • Torrent Pharmaceuticals



  • References:

  • Levetiracetam main article on Wikipedia: https://en.wikipedia.org/wiki/Levetiracetam
  • Levetiracetam compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Levetiracetam
  • Levetiracetam medicine on DrugBank: https://go.drugbank.com/drugs/DB01202
  • Levetiracetam FAQ on MedlinePlus (revised 06/15/2021): https://medlineplus.gov/druginfo/meds/a699059.html
  • Levetiracetam tablets film-coated drug label on DailyMed (revised July 1, 2021): https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Levetiracetam Teva film-coated extended release tablets drug label on DailyMed (revised December 13, 2011): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
  • Keppra (Levetiracetam) tablets film-coated and oral solution drug label on DailyMed (revised October 5, 2020): https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Keppra XR (Levetiracetam) film-coated extended release tablets drug label on DailyMed (revised October 5, 2020): https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Levetiracetam containing drugs on Drugs-About.com: https://drugs-about.com/ing/levetiracetam.html
  • Levetiracetam for sale on Pharma Doctor: https://pharma-doctor.com/levetiracetam.html
  • Keppra (Levetiracetam) tablets 250 mg, 500 mg, 750 mg, 1000 mg and solution 100 mg/mL for oral use official prescribing information and medication guide from the U.S. FDA (revised 10/2019): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Keppra (Levetiracetam) injections for intravenous use 500 mg / 5 mL official prescribing information from the U.S. FDA (revised 10/2019): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Keppra XR (Levetiracetam) 500 mg, 750 mg extended-release tablets for oral use official prescribing information and medication guide from the U.S. FDA (revised 04/2017): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Keppra (Levetiracetam) product information from UCB Pharma company (revised 10/2020): https://www.ucb.com/our-products/Products/keppra%C2%AE-epilepsy
  • Levepsy (Keppra generic) 250 mg, 500 mg, 750 mg film-coated tablets prescribing information from Cipla (revised 09/04/2020): https://www.ciplamed.com/content/levepsy-250500750-tablets
  • Levepsy (Keppra generic) 1000 mg film-coated tablets prescribing information from Cipla (revised 09/04/2020): https://www.ciplamed.com/content/levepsy-1000-tablets
  • Sandoz Levetiracetam tablets 250 mg, 500 mg, 750 mg, 1000 mg product monograph from Sandoz pharmaceutical company (revised May 10, 2018): https://www.sandoz.ca/sites/www.sandoz.ca/files/Levetiracetam...
  • Keppra (Levetiracetam) 250 mg, 500 mg, 750 mg, 1000 mg film-coated tablets package information leaflet on Medicines.org.uk (revised January 2021): https://www.medicines.org.uk/emc/files/pil.2293.pdf

    Revised: August 2021



    Home | Healthy Communities | Thriving Economy | Strong Nation | Sign The Pledge | About Us | Privacy Policy

    Copyright © 2011 - 2021 National Movement for America's Children. All Rights Reserved.